Stocks›Healthcare›OMER

OMER

OMEROS CORP

NasdaqResearch view

$20.08−0.25%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsSEC EDGAR FY 2020-12-31

What happened

Daily closes · dots are Wire stories

What’s next

Expected around mid November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 13, 2025 and Nov 13, 2024, after the close.

Last report

Aug 12, 2026

after the close

Every report since 2023 →

DateEventSourceNext close

Aug 12Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗—AWAITING

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

The numbers · FY2020, filed

SEC EDGAR

Revenue$73.8M−34.00%

Net income$-138.1M

EPS, diluted$-0.05+98.10%

Operating margin-166.4%

Return on equity114.3%

Debt / equity-1.98

All filed figures

Snapshot

SEC EDGAR · FY 2020-12-31

SectorHealthcare

Income$-138.1M

Sales$73.8M

Book/sh$-1.67

Cash/sh$0.15

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio4.08

Current Ratio4.12

Debt/Eq-1.98

EPS (ttm)$-0.05

EPS this Y98.1%

EPS past 3/5Y—

Sales past 3/5Y4.4%

EPS Y/Y TTM98.1%

Sales Y/Y TTM-34.0%

Shs Outstand72.39M

ROA-76.3%

ROE114.3%

ROIC-114.1%

Gross Margin—

Oper. Margin-166.4%

Profit Margin-187.0%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$41.6M

FY16

$64.8M

FY17

$29.9M

FY18

$111.8M

FY19

$73.8M

FY20

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2016	FY2017	FY2018	FY2019	FY2020
Revenue	$41.6M	$64.8M	$29.9M	$111.8M	$73.8M
Gross Profit	—	—	—	—	—
Operating Income	$-54.3M	$-43.9M	$-112.2M	$-146.0M	$-156.9M
Net Income	$-66.7M	$-53.5M	$-126.8M	$-84.5M	$-138.1M
Diluted EPS	$-1.65	$-1.17	$-2.61	$-1.71	$-2.41
Operating Cash Flow	$-51.5M	$-36.2M	$-103.7M	$-60.1M	$-100.1M
Free Cash Flow	$-51.6M	$-36.6M	$-104.3M	$-60.4M	$-100.4M

Follow the news. Track the move.

OMER story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Regulation

Jun 26

Omeros stock tumbles after EU panel rejects Yartemlea

An EU panel has rejected Yartemlea, Omeros's drug candidate, sending the stock tumbling on the regulatory setback. With revenue already down 34% YoY and the company running a -187% net margin, the failed EU approval removes a key catalyst that bulls were counting on.

Since story

+131.6%

2026-06-26 → 2026-09-25

Investing.com · 92d ago

View both sides →